KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Non-Current Debt (2016 - 2025)

Historic Non-Current Debt for Gsk (GSK) over the last 17 years, with Q3 2025 value amounting to -$20.1 billion.

  • Gsk's Non-Current Debt fell 1676.43% to -$20.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.1 billion, marking a year-over-year decrease of 1676.43%. This contributed to the annual value of -$18.7 billion for FY2024, which is 19893.08% down from last year.
  • Latest data reveals that Gsk reported Non-Current Debt of -$20.1 billion as of Q3 2025, which was down 1676.43% from -$20.4 billion recorded in Q2 2025.
  • Gsk's 5-year Non-Current Debt high stood at $27.8 billion for Q4 2021, and its period low was -$31.8 billion during Q1 2021.
  • Moreover, its 5-year median value for Non-Current Debt was -$20.1 billion (2025), whereas its average is -$14.5 billion.
  • Its Non-Current Debt has fluctuated over the past 5 years, first skyrocketed by 6046.69% in 2022, then plummeted by 19954.91% in 2024.
  • Gsk's Non-Current Debt (Quarter) stood at $27.8 billion in 2021, then dropped by 28.05% to $20.0 billion in 2022, then dropped by 5.55% to $18.9 billion in 2023, then crashed by 199.55% to -$18.8 billion in 2024, then fell by 6.95% to -$20.1 billion in 2025.
  • Its Non-Current Debt stands at -$20.1 billion for Q3 2025, versus -$20.4 billion for Q2 2025 and -$20.7 billion for Q1 2025.